Tumor-Mediated Suppression of Dendritic Cell Vaccines

2004 ◽  
Author(s):  
Emmanuel T. Akporiaye
Keyword(s):  
Dendritic Cell ◽  
Dendritic Cell Vaccines

scholarly journals EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii306-iii306
Author(s):  
Daniel Landi ◽  
Gary Archer ◽  
Timothy Driscoll ◽  
Eric Lipp ◽  
Bridget Archambault ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Phase I ◽  
Malignant Glioma ◽  
Phase I Trial ◽  
Active Immunization ◽  
Monocyte Differentiation ◽  
Dendritic Cell Vaccines ◽  
Dc Vaccines ◽  
Subsequent Phase ◽  
Children And Young Adults

Abstract BACKGROUND Recurrent medulloblastoma and malignant glioma are lethal tumors that are virtually incurable. The cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed on medulloblastoma and malignant glioma but not on healthy brain. We evaluated autologous CMV pp65 RNA-pulsed dendritic cell (DC) vaccines in children and young adults in a phase I trial. METHODS Circulating monocytes were harvested using leukapheresis, differentiated into DCs, matured, and pulsed with pp65 RNA using electroporation. DCs were packaged into vaccines (2x107DC/vaccine) and administered intradermally following tetanus-diphtheria toxoid site preconditioning every 2 weeks x3, then monthly. The primary objectives of the study were to establish the feasibility of generating at least 3 vaccines and safety. An exploratory objective was to evaluate the ability of vaccination to create and enhance patient pp65-specific T cell responses. RESULTS Eleven patients were enrolled with medulloblastoma (n=3) or glioblastoma (n=8). Ages ranged from 9–30 years old (mean 15.5y). Ten of 11 patients (91%) generated at least 3 vaccines (mean 6.2). Eight patients received at least 3 vaccines. To date, 4 patients have received all generated vaccines without progression, 4 patients have progressed, and 2 patients are still receiving vaccines. There have not been any severe adverse events probably or definitely related to vaccines. More mature data will be presented at ISPNO. CONCLUSIONS Leukapheresis and monocyte differentiation is a feasible strategy for generating adequate DCs for active immunization in children with malignant brain tumors. CMV pp65 RNA-pulsed DCs are well-tolerated and immunogenic. Efficacy endpoints will be evaluated in a subsequent phase II trial.

scholarly journals Peptide and Dendritic Cell Vaccines

2006 ◽  
Vol 12 (7) ◽  
pp. 2342s-2345s ◽  
Author(s):  
Craig L. Slingluff ◽  
Victor H. Engelhard ◽  
Soldano Ferrone
Keyword(s):  
Dendritic Cell ◽  
Dendritic Cell Vaccines

The Role of NY-ESO-1 Activated Dendritic Cell Vaccines in Treating Advanced Non-small Cell Lung Cancer

CHEST Journal ◽  
2016 ◽  
Vol 149 (4) ◽  
pp. A313
Author(s):  
Yu Dan ◽  
Jianli Tang ◽  
Qiasheng Li ◽  
Huanhuan Zhang ◽  
Chengzhi Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cell ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dendritic Cell Vaccines

Dendritic cell vaccines for cancer therapy

2001 ◽  
Vol 27 (4) ◽  
pp. 247-255 ◽  
Author(s):  
G.M. Sprinzl ◽  
L. Kacani ◽  
A. Schrott-Fischer ◽  
N. Romani ◽  
W.F. Thumfart
Keyword(s):  
Dendritic Cell ◽  
Cancer Therapy ◽  
Dendritic Cell Vaccines

Alternative approaches in the closed system manufacturing for dendritic cell vaccines

Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S28
Author(s):  
A.J. Dafferner ◽  
H. c. Britton ◽  
P. Warkentin ◽  
J. Talmadge
Keyword(s):  
Dendritic Cell ◽  
Closed System ◽  
Dendritic Cell Vaccines ◽  
Alternative Approaches

scholarly journals Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer

2006 ◽  
Vol 118 (9) ◽  
pp. 2220-2231 ◽  
Author(s):  
Tobias Hahn ◽  
Irene Alvarez ◽  
James J. Kobie ◽  
Lalitha Ramanathapuram ◽  
Sharon Dial ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cell ◽  
Tumor Lysate ◽  
Short Term ◽  
Dendritic Cell Vaccines

scholarly journals Multiple Myeloma and Dendritic Cell Vaccines

2021 ◽  
Vol 14 (3) ◽  
pp. 370-377
Author(s):  
Irina Vladimirovna Gribkova ◽  
A.A. Zavyalov
Keyword(s):  
Multiple Myeloma ◽  
Dendritic Cell ◽  
Dendritic Cell Vaccines

scholarly journals Dendritic cell vaccines for melanoma: past, present and future

2016 ◽  
Vol 3 (4) ◽  
pp. 273-289 ◽  
Author(s):  
Robert O Dillman ◽  
Gabriel I Nistor ◽  
Andrew N Cornforth
Keyword(s):  
Dendritic Cell ◽  
Dendritic Cell Vaccines
Sign in / Sign up

Export Citation Format

Share Document